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Background: There is limited evidence of the unmet needs and experiences of adults with Attention Deficit
Hyperactivity Disorder (ADHD) in the published scientific literature. This study aimed to explore the experiences of
adults in England with ADHD regarding access to diagnostic and treatment services, ADHD-related impairment and
to compare experiences between patients diagnosed during adulthood and childhood.
Methods: In this qualitative study, 30 adults with ADHD were recruited through an ADHD charity (n = 17) and two
hospital outpatient clinics for adults with ADHD in England (n = 13). Half of the participants were diagnosed with
ADHD during childhood or adolescence and the remainder during adulthood. Semi-structured interviews were
conducted and data was analysed using a thematic approach based on Grounded Theory principles.
Results: Analysis revealed five core themes: ‘An uphill struggle’: the challenge of accessing services, ‘Accumulated
Psychosocial Burden and the Impact of ADHD’, ‘Weighing up Costs vs. Benefits of ADHD Pharmacological
Treatment’, ‘Value of Non-pharmacological Treatment’ and ‘Barriers to Treatment Adherence’. Accessing services and
the challenges associated with securing a definitive diagnosis of ADHD in adulthood was an ‘uphill struggle’, often
due to sceptical and negative attitudes towards ADHD by healthcare professionals. ADHD-related impairment had
an overwhelmingly chaotic impact on every aspect of patients’ lives and many felt ill equipped to cope. A
persistent sense of failure and missed potential from living with the impact of ADHD impairment had led to an
accumulated psychosocial burden, especially among those diagnosed from late adolescence onwards. In contrast,
positive adjustment was facilitated by a younger age at diagnosis. Although medication was perceived as necessary
in alleviating impairment, many felt strongly that by itself, it was inadequate. Additional support in the form of
psychological therapies or psycho-education was strongly desired. However, few patients had access to non-
pharmacological treatment. In some, medication use was often inadequately monitored with little or no follow-up
by healthcare professionals, leading to poor adherence and a sense of abandonment from the healthcare system.
Conclusion: The findings suggest that the unmet needs of adults with ADHD are substantial and that there is a
wide gap between policy and current practice in England.
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Attention deficit hyperactivity disorder (ADHD) is a
neurodevelopmental disorder, which, until recent years,
has been perceived as a disorder restricted to childhood
[1]. Yet follow-up studies of children with ADHD clearly
demonstrate that the disorder often persists into adult-
hood [2,3], affecting around 2-4% of adults in the UK
and worldwide [1,4-7]. In the majority of patients diag-
nosed in childhood, ADHD impairment and symptoms
continue to be problematic in adult life [3,8]. In adult-
hood, ADHD symptoms typically feature inattention,
impulsivity, restlessness, disorganisation and forgetful-
ness, similar to characteristics in childhood [5,6,9]. This
can result in significant impairments across multiple
domains of adult life, affecting interpersonal relation-
ships, family dynamics, education, occupation and over-
all health-related quality of life [1,10,11]. For instance,
adults with ADHD are at increased risk of divorce or
separation, unemployment, imprisonment and academic
failure [10-12].
In addition, many adult patients with ADHD have
gone unrecognised and undiagnosed in childhood and
approach health services to seek help for the first time
in adulthood [13]. ADHD is often misdiagnosed in these
individuals, and the presence of co-existing disorders,
such as depression or anxiety, may contribute further to
this problem [5,13]. If ADHD is misdiagnosed, this can
result in ineffective pharmacological and non-pharma-
cological treatments being prescribed, which in some
cases may be detrimental to the individual and would
not usually alleviate their ADHD-related symptoms. Fur-
thermore, there is often a substantial psychosocial and
functional burden associated with undiagnosed and un-
treated ADHD [14]. Yet there is very little understanding
of the perspectives of adults with ADHD reported in the
scientific literature [15,16], particularly regarding access
to services and how experiences may differ between
those diagnosed in childhood and those in adulthood.
Previous studies in this patient population have mostly
employed quantitative approaches [17,18] which are lim-
ited at investigating patients’ perspectives as they restrict
the range of responses from participants. Qualitative ap-
proaches are more appropriate at providing an in-depth
insight into patients’ experiences [19].
Recent guidelines by the National Institute of Health
and Clinical Excellence (NICE) have recommended path-
ways of care for children and adults with ADHD in the
UK [20,21]. In particular, NICE recommends the use
of pharmacological treatments that have been shown
to be effective in adults with ADHD, mainly the sti-
mulants methylphenidate, dexamphetamine and atomo-
xetine [1,22]. In addition, NICE guidelines state that drug
treatment should always be part of a comprehensive treat-
ment program addressing psychological, behavioural andeducational/employment needs [20,21]. However, no re-
search to date has investigated patients’ experiences of
accessing the range of ADHD treatments in England or
patients’ attitudes and experiences regarding both phar-
macological and non-pharmacological treatment. This is
needed as it may suggest ways of promoting optimal func-
tioning in adult patients with ADHD.
Therefore, this study aimed to better understand the
health care and treatment-related experiences and needs
of adults with ADHD, specifically, to explore: a) patients’
experiences of accessing services and receiving a diag-
nosis of ADHD; b) patients’ experiences of ADHD treat-
ment, both pharmacological and non-pharmacological;
c) patients’ experiences of ADHD-related impairment;
and finally, d) to compare the experiences between adult
patients diagnosed in childhood and in adulthood.
Methods
Methodological approach
A qualitative approach using semi-structured interviews
was used as it enabled a detailed and in-depth explo-
ration of patients’ experiences and views. Moreover, the
technique is particularly useful at improving knowledge
of poorly understood areas of health care [19,23]. Face-
to-face interviews were chosen due to the sensitive and
potentially distressing nature of the research topics.
Sample
Participants were eligible for the study if they had re-
ceived a diagnosis of ADHD (self-reported), were over
18 years old, living in England, and had previous or
current experience of ADHD pharmacological treatment
for a minimum duration of 3 months. Participants were
ineligible if they were unable to participate in a face-to-
face interview. Stratified sampling was used to recruit a
total of 30 participants from two different subgroups of
adult ADHD patients:
Group 1: Adult patients who were diagnosed and
commenced pharmacological treatment for ADHD
during childhood or adolescence (under age 18).
Group 2: Adult patients who were diagnosed and
commenced pharmacological treatment for ADHD
during adulthood (aged 18 or over).
Both groups included participants who had been on
treatment without a break (continuous care), and others
who had periods of at least 6 months without care or
treatment (non-continuous care). In total, 15 partici-
pants were recruited where ADHD was first diagnosed
in adulthood and 15 were recruited where the diagnosis
was made during childhood or adolescence. This sample
size is deemed sufficient in qualitative research [24] in
terms of generating thematic saturation for most topics.
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maximise the range of participants within each category,
such as age, gender and symptom severity.Recruitment
Ethical approval was obtained from the Cambridgeshire
1 National Health Service (NHS) ethics committee (REC
reference: 10/H0304/20) and research governance ap-
proval from appropriate NHS Trust sites. Patient in-
terviews were conducted between December 2010 and
June 2011. Participants were recruited via two methods
and the process is summarised in Figure 1. Seventeen
patients were recruited through the National Atten-
tion Deficit Disorder Information and Support Service
(ADDISS) charity, which has nationwide members. Invi-
tation letters were posted to 50 adults with ADHD and
70 parents of adults with ADHD, requesting them to
pass on details of the study to their son or daughter. A
freepost envelope was enclosed with the invitation letter.
The study was also advertised in an online ADDISS
newsletter and was also emailed out to the member
database on two occasions. If participants indicated by
post or email that they were willing to participate, a con-
venient date and location was arranged for the interview.
Furthermore, 13 patients were recruited from two NHS
outpatient clinics for adults with ADHD in London and
the South East of England. The reason for recruitingFigure 1 Study response rate.from both a healthcare and non-healthcare setting was
to try to capture a range of experiences and views and to
minimise bias from recruiting from just one source.Data collection
Semi-structured face-to-face interviews were conducted
in either the participant’s home (n = 15), in a private
room at the School of Pharmacy in London (n = 12)
or at an alternative convenient location (n = 3). A
semi-structured interview guide was developed by a
multi-disciplinary team including two psychologists, a
pharmacist and a psychiatrist. This was used to guide
the discussion in each individual interview, and enabled
the interviewer to follow-up on any unanticipated issues
that arose during interviews. Written informed consent
was obtained from all participants prior to interview.
Participants were reassured that the interviews were
confidential and transcripts would be anonymised. The
interview guide involved a series of open-ended ques-
tions, and topics included accessing services, treatment
(non-pharmacological and pharmacological) and ADHD-
related impairment. Prompts were used where necessary
to elicit more detailed responses. Participants were free to
respond in their own words and the researcher followed
up on topics that arose outside of the interview guide.
The interviews lasted approximately 1 hour and were
digitally-recorded, with participants’ consent. Field notes
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researcher’s thoughts, feelings and reflections about the
interview.
In order to describe the sample, participants also com-
pleted a brief survey to obtain self-reported demographic
characteristics, prescription medication use, and ADHD
symptoms and impairment. The symptom severity check-
list is a validated questionnaire also known as the Adult
ADHD Self Report Scale (ASRS v.1) [25]. The impairment
checklist [26] is a non-validated questionnaire which asks
participants to rate (scale of 1 to 5, with high scores indi-
cating greater impairment) their level of impairment for
different domains e.g. home life.
Data analysis
Qualitative data
Interviews were transcribed verbatim and a general the-
matic approach was used to analyse the transcripts using
key principles of Grounded Theory [27,28]. A Groun-
ded Theory approach is an inductive methodology that
allows theory to be developed from the systematic gathe-
ring and analysis of data. Each transcript was read and
re-read several times, then initially coded line-by-line.
This process was repeated for each transcript and then
codes were defined and categorised into sub themes and
meta themes. The analysis was an iterative process, as
transcripts were constantly revisited when new themes
emerged. Data collection and analysis occurred simul-
taneously, so that any initial themes or unanticipated
topics arising from the data were followed up in subse-
quent interviews. Transcripts were then analysed as a
whole by the process of constant comparison [28], and
overarching themes emerged across the entire data set.
A reflexive research diary was kept during the entire
research process by LM to record any thoughts regar-
ding emerging codes or ideas resulting from the analysis
[29]. To ensure reliability, two researchers (SC and LM)
independently coded the first 4 interviews then 3 further
randomly selected interviews as data collection pro-
gressed. After comparison and discussion of codes and
understanding of the transcripts, there was a high degree
of agreement on the major themes and sub themes.
Some sub themes were phrased differently, but this was
usually due to differences in terminology, rather than
the meaning of emerging concepts. An expert psychia-
trist (PA) specialising in ADHD in adults reviewed a
summary of the initial themes and verified the themes
for face validity. In order to further ensure validity,
member checking [29] was conducted with a random
sample of participants (n = 4), who were sent a short lay
summary of their individual interviews. All respondents
agreed that the interpretation of the interview was ac-
curate. A qualitative software program (NVivo v.9) [30]
was used to assist with organising the themes. A datasaturation matrix was generated, which illustrated that
thematic saturation was achieved as no new themes were
emerging.
Quantitative data
Quantitative data was entered and analysed using SPSS
v. 18 ™. As data were collected for descriptive purposes,
only descriptive statistics were performed. Self-reported
demographic characteristics and prescription medication
use were reported as mean (SD) for continuous varia-
bles or n (%) for categorical variables. For the ASRS [25]
scale, patients’ self-reported symptom ratings were reco-
ded to 0 or 1, indicating symptoms consistent with ADHD
according to the ASRS. Scores were also recoded to 0, 1, 2
or 3 to indicate ‘none’, ‘mild,’ ‘moderate’ or ‘severe’ ADHD
symptoms. The Impairment scale was recoded to reflect
the number of scores which indicated that ADHD impair-
ment was definitely present for each of the 10 domains.
The mean (SD) and range of the total scores are reported.
Results
Thirty participants were included in this study. The sam-
ple included 15 participants diagnosed in childhood or
adolescence (of which 8 had continuous care) and 15
participants diagnosed in adulthood (of which 8 had
continuous care). There were 13 males and 17 females
with an age range of 18 to 57 years (mean age 34.9 years,
SD = 14.6). The response rate from ADDISS was 15%,
excluding those who were ineligible or responded after
study completion. Excluding those who responded after
the study finished, the response rate from the NHS out-
patient clinics was 19%. An overview of recruitment is
shown in Figure 1 and participants’ characteristics are
displayed in Table 1.
Participants reported that they were diagnosed with
ADHD between the ages of 6 and 57 years (mean age
at diagnosis = 26 years, SD = 16.8). In participants diag-
nosed in adulthood, the mean age at diagnosis was 40.93
years (SD =9.32), and 11.07 years (SD = 4.50) in partici-
pants diagnosed in childhood. As expected, there were
differences between participant groups in terms of age,
due to inherent age differences in the subgroups of
interest.
Patients self-reported medical and treatment charac-
teristics data is reported in Table 2.
The mean total score was 13 (SD = 3.20, range 6–18)
out of a total of 18, which indicates moderate symptom
burden across the sample. Participants diagnosed in
adulthood had numerically higher mean total scores (14,
SD = 2.87, range 8–18) compared to those diagnosed
in childhood (12, SD = 3.47, range 6–17). The mean
number of items which indicated that ADHD impair-
ment was definitely present was 5 out of a total of
10 (SD = 2.95, range = 0-9). Participants diagnosed in
Table 1 Demographic details
Diagnosed
in adulthood
(n = 15) N (%)
Diagnosed
in childhood
(n = 15) N (%)
Gender
Males 6 (40) 7 (47)
Females 9 (60) 8 (53)
Age Range (years)
18-25 0 (0) 13 (87)
26-35 1 (7) 1 (7)
36-45 6 (40) 0 (0)
46-55 5 (33) 1 (7)
56+ 3 (20) 0 (0)
Ethnicity
Caucasian 12 (80) 12 (80)
White other 1 (7) 2 (13)
Asian 1 (7) 0 (0)
Black 0 (0) 1 (7)
Other 1 (7) 0 (0)
Work Status
Student 2 (13) 5 (33)
Full time 4 (27) 3 (20)
Part time 5 (33) 5 (33)
Unemployed 4 (27) 2 (13)
Living Arrangements
Live alone 4 (27) 3 (20)
Live with parents 1 (7) 10 (67)
Live with spouse 6 (40) 2 (13)
Live with children 4 (27) 0 (0)
Education Status
GCSE or equivalent 2 (13) 6 (40)
A-level or equivalent 1 (7) 6 (40)
Undergraduate degree 6 (40) 2 (13)
Postgraduate degree or higher 6 (40) 1 (7)
Table 2 Medical and treatment characteristics
Diagnosed
in adulthood
(n = 15) N (%)
Diagnosed
in childhood
(n = 15) N (%)
Current Medication use
Using Medication 13 (87) 12 (80)
Discontinued Medication* 2 (13) 3 (20)
Current Medication Type
Methylphenidate 10 (77) 11 (92)
Atomoxetine 1 (8) 1 (8)
Dexamphetamine 2 (15) 0 (0)
Duration Since Diagnosis
< 1 year 1 (7) 0 (0)
1-5 years 4 (27) 2 (13)
6-10 years 7 (47) 4 (27)
11-15 years 2 (13) 8 (53)
16+ years 1 (7) 1 (7)
Duration on ADHD Medication**
(n = 24)
< 1 year 5 (42) 3 (25)
1-5 years 4 (33) 2 (17)
6-10 years 2 (17) 5 (42)
11-15 years 0 (0) 2 (17)
16+ years 1 (8) 0 (0)
*Discontinued for a period of 6 months or longer.
**missing data for 6 participants.
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pairment (6, SD = 2.55, range 1–9) than those diagnosed
in childhood (4, SD = 3.14, range 0–9). Twenty seven per
cent of the sample reported mild symptom severity, 63%
reported moderate and 10% reported severe symptom
severity. This demonstrates that the sample included a
range of different symptom severities.
Five meta-themes emerged from the qualitative data:
‘An uphill struggle’: the challenge of accessing services,
‘Accumulated Psychosocial Burden and the Impact of
ADHD’, ‘Weighing up Costs vs. Benefits of ADHD Phar-
macological Treatment’, ‘Value of Non-pharmacologicalTreatment’ and ‘Barriers to Treatment Adherence’ with
a common thread of ‘Unmet needs’ which runs through-
out participants’ experiences of treatment and accessing
services.
These themes and subthemes are presented below,
with illustrative quotes from study participants.
Theme 1: ‘An uphill struggle’: the challenge of accessing
services
Perceived barriers to accessing care
Getting a diagnosis and accessing ADHD services was
often a long and arduous process, particularly in those
diagnosed in adulthood (“I had to fight tooth and nail
for two years to get this on the NHS, it was extremely
difficult” P4). Many faced multiple barriers to getting
care, often perceived by patients to be due to overwhel-
mingly negative and sceptical attitudes towards ADHD
by health professionals. Some General Practitioners
(GPs) were perceived by patients as unwilling to refer to
specialist services because of disbelief in the condition
or poor awareness of adult ADHD (“It was an uphill
struggle” P3). Getting a definitive diagnosis of ADHD
was a challenge in those without access to specialist
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countries outside the UK (mainly in the United States);
there was a stark contrast between these positive experi-
ences and the difficulties encountered upon accessing
continued care in England.
Participants reported that the struggle of getting access
to services in adulthood exacerbated their feelings of
disempowerment, distress and helplessness and led to a
downward spiral in functioning. In several cases, delays
in accessing care left participants feeling unable to cope,
prompting periods of severe functional impairment, de-
pressive mood and even suicidal ideation (“Putting some-
body with ADHD through a bureaucracy is torture.... it’s
like treating a diabetic in a bakery” P21). Due to these
emotional difficulties, a few with particularly negative
experiences of accessing care even considered whether
getting a diagnosis was worthwhile, because of the lack
of subsequent support received (“I was very lucky to get
a diagnosis, but the diagnosis really is not very helpful
without appropriate support… it’s disgraceful there just
isn’t a system” P2).
Accessing prescription medication for ADHD was also
problematic, as some patients reported GPs being un-
willing to prescribe, or had encountered pharmacists
who were reluctant to stock or dispense ADHD medica-
tion. Therefore, some had to take multiple trips to the
pharmacy every month to collect medications, which
was stressful due to difficulties in getting organised and
remembering (“the psychiatrists but often mostly phar-
macists act as if [ADHD drug] is plutonium and it’s, like,
ridiculous” P21). Some participants recalled periods of
time where their doctor refused to prescribe the medica-
tion for them; this varied from several days to several
years. Patients reported that this was often due to doc-
tors who held negative attitudes towards prescribing
ADHD medication or health trusts that refused to fund
medication. These periods of enforced cessation were
highly distressing, and long periods without medication
led to severe emotional distress and functional impair-
ment in some.
Some reported problems with transitioning from child
to adult services, such as discontinuation of treatment
or support upon reaching 18, or delays with referrals to
adult services (“There are places you can go as a kid, but
not as an adult, it’s kind of swept under the carpet as
soon as you reach 18” P15). Overall, more positive expe-
riences of using ADHD services in adulthood were
reported from those diagnosed during childhood, or with
access to private healthcare.
Doctor-patient communication issues
A few participants experienced problems communica-
ting difficulties associated with their ADHD to their GP,
and reported becoming overly emotional during initialconsultations (“He’d [GP] just seen me crying and sha-
king and saying I have difficulty concentrating so I don’t
blame him for thinking I was in pieces really” P5). Some
participants were distressed at being unable to access
ADHD specialist care and being placed on repeat pre-
scriptions by their GP, without monitoring or support.
This was deemed inadequate at meeting their needs and
resulted in feelings of abandonment by the healthcare
system, especially in those treated since childhood. For
example, many participants whose primary interaction
was with a GP strongly desired support with adjusting
their medication type and dosage, or advice regarding
coping with side effects, but did not receive it. Evidently,
those with little support by health professionals reported
poorer self-efficacy (confidence in their ability to effec-
tively self-manage their condition).
In those who had experienced severe difficulties ac-
cessing care, a few participants felt unwilling to disclose
the negative effects of pharmacological treatment to physi-
cians over fears of medication being withheld (“I got quite
bad [side effects], but I didn’t want to tell the GP that be-
cause any excuse, I felt any excuse they’d have to stop the
meds…so that was rather miserable for a time” P3). Some
desired greater involvement in treatment decision-making
and access to a wider range of ADHD medication in order
to improve functioning and reduce side effects. In con-
trast, those with access to ADHD specialist care re-
ported that they received and strongly valued this type of
support.
Patients discussed several unmet needs regarding con-
sultations with psychiatrists. Many wanted to receive
more informed advice to help shape realistic expecta-
tions of both short and long-term medication effects, as
some detected reluctance amongst healthcare profes-
sionals to discuss potential risks. A few participants felt
that consultations with psychiatrists focused too strongly
on the impact of drug treatments, rather than on the
condition itself, which was thought inappropriate for ad-
equately supporting those diagnosed later in life. There-
fore, some felt that psychiatrists should assume a more
holistic approach to care and also focus on the psycho-
social impact of ADHD.
Many participants desired more frequent monitoring
and support, although others did already receive this.
Some participants perceived an unwillingness amongst
health professionals to help patients adjust medication
types or dosages, which was deemed important to find
optimal treatment and reduce side effects (“there isn’t
really a kind of willingness or the time available or the
knowledge available to tweak around with it [medica-
tion]” P2). In addition, participants often experienced
problems remembering to attend healthcare appoint-
ments, and they felt the need for easier access to care,
such as more telephone follow-up consultations.
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impact of ADHD
Accumulated psychosocial burden from a delayed diagnosis
Participants who went undiagnosed until adulthood of-
ten initially sought help from health care services due
to depression or anxiety complaints, which resulted in
years of misdiagnoses. The cause of co-occurring disor-
ders was attributed by many of these patients to the
underlying ADHD, as they reported long-term ADHD
symptoms since childhood. Many reported that treat-
ments for these disorders were ineffective as they failed
to address core symptoms of the ADHD. Those diag-
nosed from later adolescence onwards perceived this as
a ‘late’ diagnosis and felt a strong sense of regret and
frustration over a lack of earlier detection (“I just think
had things been understood at a younger age, I wouldn’t
constantly feel that I was a failure, I was useless, I was
sort of not worthy or I was never going to achieve any-
thing”… “because it was such a late diagnosis, the da-
mage is essentially done” P9).
In most participants diagnosed in adulthood, living
with undiagnosed ADHD had led to an accumulated
psychosocial burden due to a chronic sense of failure
and missed potential in many areas of life (“I think
that’s probably the biggest thing… is the accumulation of
shame and failed whatever, education, jobs, relationships,
there’s sort of an accumulation” P2). The emotional im-
pact of living with undiagnosed ADHD had led some to
psychological breakdown and suicidal ideation as they
felt unable to cope with the burden of impairment. Pro-
minent feelings of low self-worth in some participants
were impacted by a sense of underachievement as well
as having experienced on-going negative criticism and
labelling by others.
The impact of ADHD: a chaotic life
The impact of ADHD impairment was not limited to
those with a delayed diagnosis, but affected the whole
sample. In many participants, ADHD related impairment
had an overwhelmingly chaotic impact on every aspect
of patients’ lives. Many had struggled with the transition
into independent adult life, and often felt ill equipped to
cope (“It affects you in every single way possible” P26).
For many participants, a chronic sense of disorganisation
was particularly debilitating, due to symptoms of poor
concentration and memory (“Personal organisation is
catastrophic, it’s not good....I can’t organise my way out
of a room.... essays, dissertations, anything I spend 20
times the amount of time that someone of my general
level of brain power ought to take, I simply cannot orga-
nise stuff in my head” P4). Home and working lives were
often chaotic as many participants constantly struggled
with completing routine tasks, chronic forgetfulness,
prioritising or managing time appropriately.Most participants recalled difficulties with achieving
academically at school or university. The impact of
ADHD culminated in a sense of underachievement in
many aspects of participants’ lives, which was more
evident in those diagnosed in adulthood, although some
diagnosed during childhood still expressed feelings of
unfulfilled potential despite an earlier diagnosis and
treatment. Although several participants diagnosed
in adulthood were highly educated, many reported a
sense of underachievement in other areas of life such
as interpersonal relationships or in work roles, for
example.
ADHD had a considerable impact on work, as some
struggled to find suitable work roles. Four participants
who were graduates were unemployed, citing ADHD dif-
ficulties as the reason. Of those working, many felt inef-
ficient at work due to difficulties with procrastination,
perfectionism and concentration and felt that their work
output was poor. The negative impact of ADHD on
participants’ working lives appeared greater in those
with a delayed diagnosis, although many in the child-
hood group were still students.
Social impairment was discussed by many, as partici-
pants reported frequent conflict and relationship break-
down, particularly those diagnosed in adulthood. Many
had problems with impulsively blurting inappropriate
comments and often felt misinterpreted by others as
‘blunt’ or ‘rude’. Social impairment meant that many had
difficulty maintaining long-term friendships. Some dis-
cussed the deleterious impact of impulsivity in terms
of previous drug and alcohol abuse, reckless decision-
making and involvement in criminal behaviour, which
was reported by participants as being detrimental to re-
lationships, finances and personal safety.
Emotional impairment was evident in all participants,
particularly overreactions of frustration or anger, as
many had difficulty coping with emotions which could
become overwhelming. Some experienced periods of
emotional breakdown and functional disability, as they
were unable to complete simple tasks. According to par-
ticipants, ADHD was detrimental to physical wellbeing,
due to difficulties transitioning from sleep to wake and
vice versa. Participants diagnosed in childhood perceived
certain ADHD symptoms to have lessened since adoles-
cence, particularly hyperactivity, although many reported
feelings of restlessness or being constantly “on the go”
(P24). A few female participants reported internalised
hyperactivity, such as overactive thoughts and finding
it difficult to relax (“My mind is always working and I
can never rest, everything competes for my attention” P9).
Overall, the burden of impairment appeared greater in
those with a delayed diagnosis (from late adolescence
onwards), and positive adjustment to ADHD seemed to
be facilitated by an earlier age at diagnosis.
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pharmacological treatment
Benefits of ADHD medication: reducing the chaos
All participants discussed the benefits of pharmacolo-
gical treatment, as many felt medication lessened the
chaotic impact of ADHD, such as disorganisation and
procrastination. Some participants felt that their cogni-
tive abilities and memory were improved while on medi-
cation and several thought it improved their ability to
focus on tasks (“it was like putting on a pair of glasses
for vision; I found them excellent when it comes to
concentration…it does lift the fog” P14). Medication also
improved feelings of normalcy (“I felt normal [on medi-
cation] and the rest of the time I felt like I was on drugs”
P5). Drug treatment was often perceived as vital to daily
functioning and was deemed necessary at improving
focus in work or educational situations involving routine
tasks or written assignments. The impact on social im-
pairment was varied, as some felt medication enabled
them to function better in social situations. Medication
was thought to be beneficial at reducing emotional impair-
ment, particularly in younger participants who felt more
able to control anger or restlessness and hyperactivity.
Perceived costs of ADHD medication
Participants also weighed up the negative aspects of
pharmacological treatment. Around two thirds of the
sample reported side effects, which varied greatly bet-
ween participants, such as insomnia, headaches or poor
appetite. A few reported severely impairing side effects
such as paranoia and many experienced daily withdrawal
symptoms as medication wore off. Some participants
perceived a loss of self-identity, and felt that medication
diminished positive aspects of ADHD, such as sociability
(“When I’m on my tablets I’m a totally different person. I
can’t socialise. I am so socially awkward” P11).
A few treated from an early age felt that medication ef-
fectiveness reduced in the long-term, which meant chan-
ging drug type every few years. More negative beliefs
towards drug effectiveness were found in those who had
received inadequate specialist support to find optimum
treatment (“I need to know the reasons why I’m taking it
[medication] and what effects I can expect because other-
wise the negative sides of things outweigh it” P10). In
addition, a few participants expressed disappointment
over medication effects, and perceived a lack of long-
term improvement, particularly in the group diagnosed
in adulthood that had medication as a standalone treat-
ment. Some participants who felt that the disadvantages
of medication outweighed the advantages, were also
more often in this group, than those diagnosed in child-
hood. A few participants also reported overenthusiastic
psychiatrists raising overly high expectations of medica-
tion effectiveness.Perceived limitations of medication for ADHD
Overall, although most participants felt that drug treat-
ment was necessary at alleviating ADHD impairment
(“It’s been a life saver for me” P21), many participants,
particularly those diagnosed from late adolescence on-
wards, felt that medication as a standalone treatment
was limited. These participants reported a plethora of
unmet psychosocial needs as many strongly desired ad-
ditional psychological or educational support alongside
medication to improve functioning. However, few had
access to non-pharmacological treatment (“I think it’s ef-
fective [medication] for say maybe 30% of the condition.
30% of the condition it doesn’t deal with and the other
30% is actually the effect the condition has had on you
all your life without knowing’ …‘so it’s really, really good
but it’s not the whole story and it’s not enough. There
needs to be more work on counselling” P19). Most partic-
ipants felt that the system of care should offer more hol-
istic treatment programs (“I mean meds help but they’re
not the entire answer....it’s the stuff other than the meds
that’s there’s a real gaping hole and it’s got to tie in to-
gether…that sort of holistic management” P3). In particu-
lar, improving organisational and coping skills, reducing
stress and alleviating social and emotional impairments
was deemed necessary by many.
Theme 4: perceived value of non-pharmacological
treatment
Equal value was placed on psychosocial and pharma-
cological treatments by those with experience of both
treatment types, who felt that medication alongside ad-
ditional psychosocial support was particularly effective
(“So beyond medication I am not getting any interactive
care [CBT] which I have always found is as important as
the medication” P28). Treatments such as Cognitive Be-
havioural Therapy (CBT), Counselling or Life Coaching
were deemed beneficial by some, particularly at helping
patients learn practical coping strategies and deal with
the psychosocial burden. The social element of group
therapy or support sessions was highly valued, enab-
ling participants to learn how others coped with ADHD
(“The medication has been a great help but I know when
I went through the group CBT and when you got speaking
to so many different people it was great because you
also got to learn how they cope and how they can deal
with it” P24). Yet, some thought psychosocial treatments
should be better designed and more appropriate for
ADHD patients in terms of being more engaging and ac-
cessible. Participants diagnosed in childhood reported
greater access to psychosocial treatments whilst in child
services, but these were often discontinued in adulthood.
However, despite reporting greater access, these par-
ticipants placed less value on the usefulness of non-
pharmacological treatments, compared to participants
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chosocial treatments was inappropriate in adolescence
and would be more useful in helping them to cope
with adulthood challenges (“I could go back and say oh I
need help with this now, so whether it was too early, the
CBT I don’t know, being at that age” P17).
Theme 5: barriers to treatment adherence
Issues of medication non-adherence (e.g. missing doses)
and experimenting with treatment cessation (longer
periods of medication cessation) also arose in the inter-
views. Participants gave several explanations for occa-
sionally not taking their medication as prescribed. The
most commonly reported reason for non-adherence was
forgetfulness but other reasons included only taking the
medication when it was perceived as needed (“I just take
them for exams now or if there’s something going on that
I find a struggle” P1), not liking to take medication dur-
ing weekends or holidays and perceived lack of guidance
from clinicians (“Because, I don’t know, and I’m not getting
any guidance, I’m not using the tablets properly” P10).
Furthermore, many participants talked about expe-
rimenting with longer periods of medication cessation.
Reasons for cessation were: the experience of side ef-
fects, a desire to cope without medication, uncertainty
over medication effectiveness and a sense of lost self-
identity. A few participants had not been taking medica-
tion for 6 months or longer but the majority of cessation
attempts resulted in restarting treatment. Participants
talked about the negative impact that stopping treatment
had on life at home, work, school and emotional impair-
ment, such as increased feelings of anger, frustration and
behavioural problems. In many cases, participants did
not discuss cessation attempts with their physician, so
subsequently received no medical support during these
problematic times.
Discussion
These findings illustrate that accessing ADHD diagnostic
and treatment services is often an arduous and challen-
ging process for adults in England. Poor awareness and
inappropriately high levels of scepticism among health
professionals was encountered by participants, despite
recent national clinical guidelines and consensus among
experts about the diagnosis and treatment of ADHD in
adults [2,21]. On-going difficulties with accessing ADHD
medication was evident, as many perceived fearful atti-
tudes and reluctance amongst pharmacists and GPs to-
wards prescribing; this is in line with findings from a
recent review [31]. The lack of licensed ADHD medi-
cations approved for use in adults during the time of
this research may have contributed to this reluctance to
prescribe, although NICE has recommended the use of
unlicensed ADHD medications since 2008 [21]. Severefunctional and psychological impairments were reported
by participants who had found that accessing care was
particularly challenging. As previous research demon-
strates that maladaptive coping strategies in dealing with
stressful situations are present in adults with ADHD
compared to people without ADHD [17], this indicates
that adults with ADHD may be particularly vulnerable
to system-related impairment, which can have a delete-
rious impact.
Importantly, this study compared adult patients diag-
nosed with ADHD at different stages of the lifespan, and
the psychosocial burden of ADHD related impairments
appeared more severe and problematic in those diag-
nosed from later adolescence onwards (16 years or
older), who deemed this as a ‘late’ diagnosis. Based on
participants overall accounts of managing their ADHD,
those diagnosed in childhood appeared more positively
adjusted to the condition and reported fewer psycho-
social and service-related unmet needs, compared to
those diagnosed in adulthood. However some of those
diagnosed in childhood did experience problems tran-
sitioning from child to adult services; similar to findings
reported previously which suggests that pharmacological
treatment in young adults with ADHD may be discon-
tinued prematurely by health care professionals [32,33].
Evidently, ADHD related impairment had an overwhel-
mingly chaotic impact on all aspects of participants’
lives, both those diagnosed in childhood and adulthood,
supported by previous research [1,10-12,34]. Despite the
unusually high levels of educational achievement in
those diagnosed in adulthood (80% had a Bachelor de-
gree or higher), many still had an overriding sense of un-
fulfilled potential across multiple areas of life, such as
interpersonal relationships and work achievements. Al-
though the group diagnosed in childhood had much
lower educational achievements in comparison, this is
most likely a reflection of the age differences between
the groups as those diagnosed during adulthood were
older.
This study highlights that adult patients with a delayed
diagnosis of ADHD have many unmet needs regarding
treatment. According to NICE guidelines [20,21], all
ADHD patients should have a comprehensive treatment
program, with pharmacological treatment offered (me-
thylphenidate as first line treatment), unless patients
prefer psychological treatment alone. The guidelines
state that treatment should meet the psychological, be-
havioural and educational/or occupational needs of pa-
tients [20]. Yet in this study, many participants had no
access to non-pharmacological treatment on the NHS
and displayed many unmet psychosocial needs. Whilst
patients felt ADHD medication was necessary to alleviate
impairment, those diagnosed from late adolescence on-
wards expressed strong views about wanting additional
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itself was deemed inadequate and many struggled to
cope. This was also reflected by quantitative data collected
which demonstrated that symptoms and impairment were
still present despite medication use. This suggests that
there may be a wide gap between practice and NICE
guideline policy in England, in terms of the services and
support that adults with ADHD should receive [20,21].
Evidently, those patients with experience of both treat-
ment types placed equal value on pharmacological and
non-pharmacological treatments, and appeared more
positively adjusted to the condition. The potential value
of psycho-education, particularly when combined with
medication has been highlighted in a recent review
of care for children with ADHD [31]. There are rela-
tively few studies, in comparison with pharmaco-
logical studies, that have investigated the efficacy of
non-pharmacological treatments for ADHD in adult
patients, but these provide promising results and in-
dicate that this is an important area for future deve-
lopment [35-41].Figure 2 Patients’ self-reported problems regarding the ADHD systemThere were stark differences in the experiences of
those with and without access to specialist ADHD care.
Some participants were placed on repeat prescriptions
by their GP and went unmonitored with drug regimes,
which was deemed completely inadequate by partici-
pants, and is neither in line with current ADHD policy
nor with NICE guidelines [20,21]. This was one of se-
veral factors in this study which contributed to poorer
adherence and a sense of abandonment from services.
Without a specialist to give advice on adjusting medica-
tions, participants felt the optimal benefits were not
achieved and struggled to cope with side effects. Con-
versely, those who had received specialist help with fin-
ding their optimal dose strongly valued this support,
which in most cases would also have included advice on
coping strategies and psychological support. Improve-
ments to care provision were also discussed by those
with access to specialist care, and some felt that more
informative advice regarding medication and greater in-
volvement in decision-making during consultations would
be beneficial so they would feel more informed about theirof care in England.
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ticipants who were diagnosed later in adulthood, as they
felt that psychosocial issues should be discussed during
consultations in addition to drug treatment issues. A sum-
mary of patients’ self-reported problems and areas of
unmet need related to the system of care in England is
displayed in Figure 2.
There are several limitations of the current study. The
findings are based on a relatively small sample size.
However, this number is typical in qualitative research
and thematic saturation was achieved [24]. There was
also a low response rate, possibly due to the difficulties
reported by the participants regarding organisational im-
pairment as well as the possibility of outdated database
records from the ADHD charity (ADDISS) that were
used to identify potential participants. Difficulty in re-
cruitment was also reported by a previous qualitative
study in young adults with ADHD [42]. Furthermore,
exact response rates were difficult to gauge due to un-
certainty over how many potentially eligible participants
read the ADDISS newsletter. Recall bias may also have
occurred, particularly in those diagnosed in childhood,
as participants were sometimes discussing events that
happened several years ago, e.g. experience of diagnosis.
Additionally, although the gender ratio of patients with
ADHD is almost 1:1 in adults [43,44], there were more
female participants in the sample.
Further quantitative research is warranted to assess
the true extent of unmet needs in the wider adult ADHD
population in the UK as well as other countries with dif-
ferent healthcare system. Additionally, further research is
necessary to design and evaluate more appropriate psy-
chosocial interventions for providing educational and
psychological support for adults with ADHD, as there
is limited research in this area. Furthermore, exploring
physicians’ perceptions and experiences of treating adult
ADHD patients may also indicate areas for improvement
in the system of care.
The current study indicates where improvements to
practice and policy are urgently needed so that patients’
needs are met. Firstly, NICE guidelines [21] need to be
implemented in practice, in England, to minimise con-
dition and system-related impairment in adults with
ADHD. Health professionals may benefit from a greater
awareness of adult ADHD to enable earlier detection
and diagnosis when appropriate. Additionally, greater
availability of psychological or educational interventions,
particularly for patients with a delayed diagnosis, may
help patients cope better with their ADHD. Patients
with ADHD may also require additional support around
early adulthood, in those with continuing impairment, to
ensure patients adjust better with the transition from
child to adult care. Furthermore, better continuity of
care and frequent monitoring may be warranted so thatadults with ADHD are better supported to achieve opti-
mal functioning.
Conclusions
This study highlights the challenging process of acces-
sing adequate ADHD diagnostic and treatment services,
which can have a damaging impact on adult patients
with ADHD. The findings indicate that a substantial psy-
chosocial burden exists in adult ADHD patients, particu-
larly those diagnosed from late adolescence onwards.
This study also demonstrates the potential need for bet-
ter psychological and educational support for adults with
ADHD, especially patients who have a delayed diagnosis.
Overall, these findings highlight the wide gap between
recent NICE guidelines [20,21] and current practice
in England regarding the clinical care for adults with
ADHD, also supported by a recent article which argued
that adults with ADHD are “ignored and under-treated”
by services [45].
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